FDA Approved: TRUVADA — Supplemental Application (Gilead Sciences, Inc)

View source ↗

Summary

The FDA approved a supplemental application for TRUVADA (emtricitabine and tenofovir disoproxil fumarate) from Gilead Sciences, Inc., related to the NDA 021752.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

SUPPL AP for TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)